Abstract
In the clinical trials about 9% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6% were persistent and 3% transient. The occurrence of antibodies reduced serum levels of natalizumab, decreased bio-efficacy, and abrogated the therapeutic efficacy.
Original language | English |
---|---|
Journal | Multiple Sclerosis |
Volume | 17 |
Issue number | 9 |
Pages (from-to) | 1074-8 |
Number of pages | 5 |
ISSN | 1352-4585 |
DOIs | |
Publication status | Published - 2011 |
Keywords
- Adolescent
- Adult
- Aged
- Antibodies, Anti-Idiotypic
- Antibodies, Monoclonal, Humanized
- Female
- Humans
- Integrin alpha4
- Male
- Middle Aged
- Multiple Sclerosis, Relapsing-Remitting